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Four World Health Organization (WHO) Collaborating Centres for Reference and Research on Influenza
and one WHO Collaborating Centre for the Surveillance, Epidemiology and Control of Influenza (WHO
CCs) assessed antiviral susceptibility of 14,330 influenza A and B viruses collected by WHO-recognized
National Influenza Centres (NICs) between May 2015 and May 2016. Neuraminidase (NA) inhibition
assay was used to determine 50% inhibitory concentration (IC50) data for NA inhibitors (NAIs) oseltamivir,
zanamivir, peramivir and laninamivir. Furthermore, NA sequences from 13,484 influenza viruses were
retrieved from public sequence databases and screened for amino acid substitutions (AAS) associated
with reduced inhibition (RI) or highly reduced inhibition (HRI) by NAIs. Of the viruses tested byWHO CCs
93% were from three WHO regions: Western Pacific, the Americas and Europe. Approximately 0.8%
(n ¼ 113) exhibited either RI or HRI by at least one of four NAIs.
As in previous seasons, the most common NA AAS was H275Y in A(H1N1)pdm09 viruses, which
confers HRI by oseltamivir and peramivir. Two A(H1N1)pdm09 viruses carried a rare NA AAS, S247R,
shown in this study to confer RI/HRI by the four NAIs. The overall frequency of A(H1N1)pdm09 viruses
containing NA AAS associated with RI/HRI was approximately 1.8% (125/6915), which is slightly higher
than in the previous 2014-15 season (0.5%). Three B/Victoria-lineage viruses contained a new AAS, NA
H134N, which conferred HRI by zanamivir and laninamivir, and borderline HRI by peramivir. A single B/
Victoria-lineage virus harboured NA G104E, which was associated with HRI by all four NAIs. The overall6, Atlanta, GA, 30329, USA.
).
ed by Elsevier B.V. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).

































































Fig. 1. Influenza viruses collected and tested for phenoty
lineage; for specimens tested, peaks in specimen collec
viruses tested for phenotypic susceptibility to the four
sortants are shown separately.frequency of RI/HRI phenotype among type B viruses was approximately 0.6% (43/7677), which is lower
than that in the previous season.
Overall, the vast majority (>99%) of the viruses tested by WHO CCs were susceptible to all four NAIs,
showing normal inhibition (NI). Hence, NAIs remain the recommended antivirals for treatment of
influenza virus infections. Nevertheless, our data indicate that it is prudent to continue drug suscepti-
bility monitoring using both NAI assay and sequence analysis.
© 2017 The Francis Crick Institute. Published by Elsevier B.V. This is an open access article under the CC
BY license (http://creativecommons.org/licenses/by/4.0/).1. Introduction
The M2 channel blockers are no longer recommended for
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NAIs by World Health Organizatio2005; Nelson et al., 2009). The neuraminidase (NA) inhibitors
(NAIs), which include oral oseltamivir, inhaled zanamivir, intrave-
nous peramivir and inhaled long-acting laninamivir, have been
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Fig. 2. A) Number of viruses tested in the neuraminidase inhibition assays (NAI assay)
over the 2012e2016 period. B) Proportion of viruses showing RI or HRI by neur-
aminidase inhibitors (NAIs) over the 2012e2016 period. Data compiled from the global
studies reporting on viruses isolated during 2012e13 (Meijer et al., 2014), 2013e14
(Takashita et al., 2015b), 2014e15 (Hurt et al., 2016), and 2015e16 (current study). B/
Yamagata-lineage haemagglutinin:B/Victoria-lineage neuraminidase reassortants are
L.V. Gubareva et al. / Antiviral Research 146 (2017) 12e2014tightly to the active sites of influenza NAs, interfering with the
enzymatic function required for efficient replication of the viruses
and their mobility within an infected host (McKimm-Breschkin,
2013). Their availability and usage differ markedly, with oseltami-
vir being the most commonly prescribed in a number of countries,
and laninamivir being licensed only in Japan (Ison, 2017; Kubo
et al., 2010). In August 2016, the U.S. Food and Drug Administra-
tion (FDA) approved the first generic version of oseltamivir (FDA,
2016). There are substantial efforts to enhance the arsenal of anti-
influenza drugs by developing compounds with alternative mech-
anisms of action (Naesens et al., 2016); in the meantime, NAIs
remain the principal therapeutics to treat seasonal and zoonotic
influenza virus infections.
WHO Global Influenza Surveillance and Response System
(GISRS) laboratories around the world participate in surveillance
efforts aimed at rapidly detecting the emergence of influenza
strains with reduced susceptibility to NAI(s). The NAI assay is the
primary tool utilized to monitor influenza susceptibility to NAIs
through determination of the concentration of drug required to
inhibit NA enzymatic activity by 50% (IC50). A threshold (cutoff IC50
value) which could be used to reliably separate drug-resistant and
drug-sensitive viruses has not yet been established. Nevertheless,
an elevated IC50 is generally viewed as an indicator of reduced
antiviral activity of the NAI. To ensure consistency in interpreting
and reporting of NAI assay data, the World Health Organization
Expert Working Group on Surveillance of Influenza Antiviral Sus-
ceptibility (WHO-AVWG) introduced a set of criteria to define the
antiviral susceptibility of viruses based on the fold change of their
IC50. To this end, the IC50 of a test virus is compared to a reference
IC50 (e.g. a median IC50 of viruses of the same type/subtype) to
calculate a fold increase (WHO, 2012). Notably, the difference in the
baseline IC50 values of influenza A and B viruses requires a type-
specific interpretation of NAI assay data. Hence, for type A vi-
ruses, normal inhibition (NI) is reported when increases in IC50 of
less than 10-fold are detected, reduced inhibition (RI) when 10- to
100-fold increases are observed and highly reduced inhibition
(HRI) when increases of more than 100-fold are detected; for type B
viruses the corresponding fold increases are <5, 5e50 and >50
respectively (WHO, 2012). Viruses displaying RI or HRI typically
harbour changes (i.e. amino acid substitutions/deletions) within or
near the NA active site which adversely affect binding of one or
more NAIs (McKimm-Breschkin, 2013).
In 2007e2008, the unprecedented rise of seasonal A(H1N1)
viruses carrying the NA amino acid substitution (AAS) H275Y was
detected in Europe (Kawai et al., 2009); these oseltamivir-resistant
viruses rapidly spread globally. The emergence of the pandemic
A(H1N1) virus in 2009 ended their circulation, as they were dis-
placed by the antigenically novel and oseltamivir-susceptible
A(H1N1)pdm09 viruses (Garten et al., 2009). In subsequent sea-
sons, A(H1N1)pdm09 viruses containing H275Y NA AAS have been
detected in patients with and without exposure to oseltamivir
treatment, with large clusters reported in Australia and Japan (Hurt
et al., 2016; Meijer et al., 2014; Takashita et al., 2015a, 2015b). The
global spread of A(H1N1)pdm09 viruses carrying NA H275Y AAS
remains the prime concern for public health because of evidence
supporting their transmissibility in communities and dual resis-
tance to oseltamivir and peramivir (Kelso and Hurt, 2012). Other
less common NA AASs have also been reported to confer RI/HRI by
NAI(s). Such AASs can occur in influenza A and B viruses, either
spontaneously, or as a result of antiviral treatment. Hence, in order
to develop strategies for pandemic preparedness and ensure
appropriate treatment and clinical management guidelines, it is
essential tomonitor susceptibility to individual NAIs of all influenza
types, subtypes and lineages.2. Overall analysis of phenotypic antiviral susceptibility data
from WHO CCs
The GISRS monitors the evolution of influenza viruses and
provides recommendations on many influenza-related topics
(http://www.who.int/influenza/gisrs_laboratory/en/). GISRS com-
prises 143 National Influenza Centres (NICs), 6 WHO Collaborating
Centres (CCs), 4 WHO Essential Regulatory Laboratories, 13 WHO
H5 reference laboratories and ad hoc groups established to address
specific emerging issues. NICs collect virus specimens in their
country and perform initial analysis. Representative viruses of each
antigenic type and subtype/lineage are then shipped to one of the
WHO CCs for further characterization. Virus specimens are
commonly propagated in MDCK or MDCK-SIAT1 cells by WHO CCs
prior to drug susceptibility assessment using the NAI assay (Hurt
et al., 2012; World Health Organization, 2011). Viruses exhibiting
RI or HRI are subjected to sequence analysis (together with their
original clinical specimens if possible) to identify NA AASs
responsible for the altered phenotype.
The data presented in this study includes the analysis of viruses
collected between week 21/2015 (May 18, 2015) and week 20/2016
(May 22, 2016) (Fig. 1A). A total of 14,330 influenza viruses were
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Fig. 3. Column-scatter plots of log-transformed 50% inhibitory concentration (IC50) fold-change values. Data are presented by virus subtype or lineage [A) A(H1N1)pdm09; B)
A(H3N2); C) B/Victoria-lineage; and, D) B/Yamagata-lineage] and neuraminidase inhibitor (labelled on the X-axis: oseltamivir, zanamivir, peramivir, laninamivir). Panel C) also
contains B/Yamagata-lineage haemagglutinin:B/Victoria-lineage neuraminidase reassortants, of which the three with reduced inhibition are indicated with an asterix (*). The boxes
indicate the 25e75 percentile and the whiskers stretch to the lowest and highest value within 1.5 times the interquartile region value from both the 25 and 75 percentile values
respectively (Tukey's definition). The Y-axes have been split into 3 compartments according to the thresholds recommended by the World Health Organization Expert Working
Group of GISRS for normal inhibition (NI) (A viruses <10-fold; B viruses <5-fold), reduced inhibition (RI) (A viruses 10- to 100-fold; B viruses 5- to 50-fold), and highly reduced
inhibition (HRI) (A viruses >100-fold; B viruses >50-fold). For RI and HRI viruses that have been sequenced the determined AAS are shown; amino acid position numbering is A
subtype- and B type-specific. All viruses were tested for susceptibility to oseltamivir and zanamivir but not all, including some variants, were tested against peramivir and
laninamivir.
























































































































































































































































































































































































































































































































































































































































































































































































































































































































































L.V. Gubareva et al. / Antiviral Research 146 (2017) 12e2016zanamivir (Fig. 1B and Fig. S1). Two-thirds of these viruses
(n ¼ 9795) were also tested for susceptibility to peramivir and
laninamivir by the WHO CCs located in Atlanta, Melbourne and
Tokyo (Fig. 1B). Compared to previous influenza seasons, the
overall number of viruses tested increased by 7% (Fig. 2B). Among
the viruses tested during 2015e16, A(H1N1)pdm09 viruses were
most prevalent (4544; 31.7%), followed by A(H3N2) (3714;
25.9%), B/Victoria-lineage (3190; 22.3%) and B/Yamagata-lineage
viruses (2882; 20.1%) (Fig. 2A).
Similar to previous global updates, the majority of viruses
were submitted from the Western Pacific WHO region (52.8%),
followed by the Americas (30.5%) and Europe (9.6%). Small pro-
portions of the viruses were received from the WHO regions of
Africa (3.2%), Eastern Mediterranean (2.0%) and South-East Asia
(1.9%) (Fig. 1B).
Of the 14,330 viruses tested, 113 (0.8%) exhibited RI or HRI by
at least one NAI, a modest increase compared to the 2014e15
period (0.5%) (Figs. 2B and 3A-D; Tables 1 and 2). NA sequence
analysis revealed AASs in 102 of these 113 viruses. The presence
of the identified NA AASs were confirmed in 76 matching clinical
specimens and not detected in two; the remaining 24 clinical
specimens were not available for analysis (Tables 1 and 2).
3. A(H1N1)pdm09 viruses showing RI or HRI
Of the 4544 A(H1N1)pdm09 viruses tested, 79 (1.7%) exhibi-
ted RI/HRI by at least one NAI (Table 1) which is slightly higher
than in the previous season (0.5%; p < 0.001) (Fig. 2B).
The majority of these viruses exhibited RI/HRI by oseltamivir
(n ¼ 77; 15- to 20,324-fold) and peramivir (n ¼ 65; 10- to 6270-
fold), and most of them (n ¼ 74) contained the NA H275Y AAS
(Fig. 3A, Tables 1 and S1). These 74 viruses were collected in
different parts of the world: Japan (n ¼ 41), the United States of
America (n¼ 19), China (n¼ 5), Norway (n¼ 3), Australia (n¼ 2),
Singapore (n ¼ 1) Malaysia (n ¼ 1), Czechia (n ¼ 1) and Oman
(n ¼ 1) (Table S1). Of the 74 viruses, 32 (43.2%) were from NAI-
treated patients [oseltamivir (n ¼ 26), peramivir (n ¼ 5) or
three NAIs (n ¼ 1)]; 21 (28.4%) were from patients with no
antiviral treatment, while 21 (28.4%) were from patients with
unknown treatment histories (Tables 1 and S1). Eight of 74 vi-
ruses harboured mixed populations of H275Y variant and H275
wild type viruses (Table S1); five of these were from Japanese
patients treated with oseltamivir (n ¼ 4) or peramivir (n ¼ 1).
Notably, the two H275Y viruses displaying the highest fold in-
creases in IC50 each contained an addition NA AAS. The first virus
A/Hiroshima/13/2016 contained a novel NA dual AAS,
H275Y þ G147R, which conferred a 2649-fold increase in IC50.
This virus was isolated from an immunocompromised patient
who received prophylaxis with laninamivir and therapeutic
treatment with peramivir (Takashita et al., 2016). The NA G147R
AAS occurs at a low frequency in N1 subtype viruses (Hooper
et al., 2015), and confers RI by oseltamivir and zanamivir in
A(H5N1) viruses (Nguyen et al., 2013). More recently, it was
shown to confer NA N1 receptor-binding activity, while retaining
enzymatic activity and not affecting virus replication (Hooper
and Bloom, 2013; Hooper et al., 2015). NA residue 147 is
located in the 150-loop; it is possible that G147R alters the
conformation of the 150-loop due to the larger size and positive
charge of the side chain, thus adversely affecting the binding of
NAIs and having a synergistic effect with H275Y. The second vi-
rus, A/Ibaraki/54/2016, was collected from a patient treated with
oseltamivir, peramivir and laninamivir and contained NA
H275Y þ I223K dual AAS conferring 20,324-fold increase in IC50
(Tables 1 and S1). The combination of H275Y with I223K/R has






























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































L.V. Gubareva et al. / Antiviral Research 146 (2017) 12e20 17I223R narrows the NA active site pocket that accommodates the
hydrophobic pentoxyl group of oseltamivir (Hurt et al., 2011;
Van der Vries et al., 2012) and it is likely that I223K produces
a similar effect.
In addition to RI by oseltamivir, two viruses (A/India/1819/
2016 and A/Tennessee/24/2016) exhibited RI/HRI by the other
three NAIs (Tables 1 and S1) and carried S247R (Table 1). This
AAS was previously reported in two viruses, A/Sri Lanka/2356/
2011 and A/Thailand/SirirajICRC_CBI_3/2009, and in silico
studies predicted an adverse effect on oseltamivir and zana-
mivir binding (Mandal et al., 2017). Another AAS in the same
residue, S247N, was previously shown to have a mild effect on
inhibition by oseltamivir (5- to 8-fold) (Hurt et al., 2011). One
virus, A/Bayern/151/2015 exhibited borderline RI (10-fold) by
zanamivir and carried I117R (confirmed in the matching clinical
specimen), which has not been described before.
Finally, two viruses exhibited RI and contained the NA AASs
D151N/D and Q136R/Q previously associated with adaptation to
cell culture (Tables 1 and S1).
4. A(H3N2) viruses displaying RI or HRI
As in previous seasons, the frequency of A(H3N2) viruses
displaying RI/HRI remained very low (Fig. 2B). Of 3714 A(H3N2)
viruses tested, 8 (0.2%) exhibited RI by one or more NAIs.
All eight viruses were collected in the United States of
America and belonged to genetic group 3C.3a. A single virus, A/
Indiana/29/2015, exhibited RI by oseltamivir, zanamivir, per-
amivir and borderline NI (9-fold) by laninamivir (Tables 1 and
S1). The isolate and matching clinical specimen harboured NA
Q391K AAS. The remaining seven viruses displayed borderline
RI (10e15-fold) by oseltamivir. However, the RI phenotype of
these viruses was not stable upon passage (data not shown). All
viruses harboured NA K249E AAS, which has previously been
seen in viruses displaying a borderline RI by oseltamivir (Sheu
et al., 2008; Zhong et al., 2013).
5. B/Victoria-lineage viruses displaying RI or HRI
The number (n ¼ 3190) of B/Victoria-lineage viruses tested
during 2015e16was four-times higher than during the previous
season. However, the frequency of viruses displaying RI or HRI
was slightly lower, 0.5% (15/3190) versus 0.7% (Fig. 2AeB).
One virus, B/Malaysia/0471/2016 exhibited HRI by all NAIs
and harboured NA G104E AAS, which has not been described
before, but neither patient information nor clinical specimen
was available (Tables 2 and S2). A different AAS at the same
position, G104R/G, was previously reported in a B/Victoria-
lineage virus that displayed RI by peramivir (Hurt et al., 2016).
A substitution at the neighbouring residue was detected in B/
South Australia/48/2015 as a mixed population, NA E105K/E,
associated with HRI by peramivir; the mixed population was
also detected in the clinical specimen (Tables 2 and S2). This
AAS has been linked to RI by NAIs in the past (Farrukee et al.,
2015; Fujisaki et al., 2012). It has been suggested that NA
AASs at residues 104 and 105 may weaken stability of the
tetrameric NA and adversely affect binding of NAIs to the active
site (Fujisaki et al., 2012), especially in B/Victoria-lineage vi-
ruses (Farrukee et al., 2015).
Three viruses displayed HRI by zanamivir and peramivir and
borderline HRI by laninamivir (Fig. 3C) due to a novel NA H134N
AAS, which was detected in these corresponding clinical spec-
imens (Table S2) (Baranovich et al., 2017). These viruses were
collected in two widely-dispersed provinces of Lao People's
Democratic Republic (PDR) and no evidence of epidemiological
L.V. Gubareva et al. / Antiviral Research 146 (2017) 12e2018links were found (Baranovich et al., 2017). One of the patients was
hospitalized due to severe acute respiratory illness, and none of the
patients had documented exposure to NAIs prior to specimen
collection (Baranovich et al., 2017). NA H134 AAS may weaken
binding of NAIs to the NA active site, especially for antivirals con-
taining a guanidyl group, by affecting the conformation of the 150-
loop. The H134N viruses replicated well in Normal Human Bron-
chial Epithelial (NHBE) cells and ferrets (Baranovich et al., 2017).
The detection of influenza viruses displaying HRI by zanamivir in
untreated patients is rare, which has been attributed to the mini-
malistic design of this NAI and infrequent use (McKimm-Breschkin,
2013). Another AAS at the same NA residue, H134Y, was detected in
B/Christchurch/558/2015 (Tables 2 and S2) and associated with HRI
by peramivir (76-fold) and NI by the other NAIs. This AAS has been
previously reported in B/Victoria-lineage viruses showing RI by
peramivir (Takashita et al., 2015b).
Two viruses exhibited RI/HRI by peramivir and contained the NA
D432G AAS (Fig. 3C, Tables 2 and S2). This AAS was shown to confer
RI/HRI by peramivir in B/Victoria-lineage viruses (Fujisaki et al.,
2013; Leang et al., 2014). Unfortunately, the original specimens
were not available for sequence analysis.
Additionally, three viruses that displayed RI by one ormore NAIs
showed no distinctive AASs in NA sequences (Tables 2 and S2). Two
other viruses showed RI by zanamivir (14e17-fold) and contained
the dual NA AAS of T106L þ P165L and K186R þ I262T, while a
single virus showed borderline RI by zanamivir and contained the
NA AAS G243S/G as a mixed population (Tables 2 and S2). Finally, a
single virus (B/Darwin/83/2015) containing the NA AAS I221T
exhibited RI by peramivir (~8-fold); this AAS was not detected in
the clinical specimen. NA I221T AAS has been shown to confer RI by
peramivir in B/Victoria-lineage viruses (Leang et al., 2014).
6. B/Yamagata-lineage viruses showing RI or HRI
The number (n¼ 2882) of B/Yamagata-lineage viruses tested, as
well as the frequency (0.4%; n ¼ 11) of viruses displaying RI/HRI,
was lower than in the previous season (Fig. 2A and B).
Three viruses isolated in different areas of Australia exhibited RI/
HRI by peramivir and borderline RI by oseltamivir (Tables 2 and S2).
These isolates and their respective clinical specimens contained NA
H273Y AAS. This AAS has occasionally been seen in type B viruses
from both lineages (Hurt et al., 2016; Meijer et al., 2014; Takashita
et al., 2015b).
Five viruses containing D197N NA AAS were collected inwidely-
dispersed parts of the world (Tables 2 and S2). Consistent with
previous reports (Hurt et al., 2016), this AAS conferred borderline RI
by oseltamivir, zanamivir or peramivir (Table 2).
Three other viruses exhibited borderline RI by either oseltamivir
or peramivir (Tables 2 and S2). The first virus contained the I221V
NA AAS, previously reported in B/Victoria-lineage viruses circu-
lating widely in North Carolina during 2011 (Garg et al., 2013;
Sleeman et al., 2011). The second virus, B/Florida/05/2016 (isolate
and clinical specimen) contained the K152N NA AAS (Tables 2 and
S2), which has not been previously reported. Another AAS at the
same residue, K152M, was reported in a B/Victoria-lineage virus
exhibiting RI by oseltamivir (Hurt et al., 2016). The third virus had
no apparent changes in the NA sequence (Table 2).
7. Frequency of RI and HRI conferring NA amino acid
substitutions in sequence databases
The examination of NA sequences deposited in public sequence
databases is a valuable adjunct to the drug susceptibility assess-
ment. Sequences of seasonal influenza viruses collected between
May 18, 2015 andMay 22, 2016 were retrieved from two databases:the Global Initiative on Sharing All Influenza Data (GISAID) (www.
gisaid.org) and National Centre for Biotechnology Information
Influenza Virus Resource (NCBI-IVR) (www.ncbi.nlm.nih.gov/
genomes/FLU/FLU.html). Sequences were curated by excluding
those incomplete and/or duplicated (based on the strain designa-
tion), resulting in NA sequences for 13,484 influenza viruses
(Fig. S1); approximately two-times the number during the 2014e15
reporting period (Hurt et al., 2016). The sequences were examined
for substitutions previously reported to confer RI/HRI, as listed on
the WHO GISRS website (http://www.who.int/influenza/gisrs_
laboratory/antiviral_susceptibility/avwg2014_nai_substitution_
table.pdf), as well as, additional AAS recently reported.
Based on the strain designation, we found that 8786 of the
deposited sequences corresponded to viruses tested in NAI assay by
WHO CCs, of which, 8673 belonged to viruses displaying NI
(Fig. S1). Considering that some of them could harbour mixtures of
wildtype and variant NA, and still exhibit a NI phenotype, it was
prudent to inspect their sequences. Indeed, sequences of four
A(H1N1)pdm09 virus isolates from Japan contained a NA H275Y/H
mix; these viruses were collected from patients treated with osel-
tamivir (Table S3). In addition, A/Argentina/22/2015, contained NA
I223T AAS, which conferred RI by oseltamivir in another A(H1N1)
pdm09 virus (Takashita et al., 2015b). A group of 38 A(H1N1)pdm09
viruses contained NA AAS at E119 or Q136 (Table S3). The emer-
gence of these variants could possibly be attributed to host-cell
selection (Table S3). Although five of these sequences were re-
ported as E119K, it is likely that an E119K/E mix was present in the
virus isolate tested; clean E119K AAS, was shown to drastically
diminish NA activity (Samson et al., 2014).
Three sequences of A(H3N2) viruses displaying NI contained the
following AASs: E119V/E, R292K/R and Q136K/Q (Table S3). E119V is
known to confer HRI by oseltamivir, while R292K confers HRI by
oseltamivir/peramivir and RI by zanamivir/laninamivir. Q136K has
been previously associated with virus adaptation to cell culture
(Little et al., 2015).
Analysis of B/Victoria-lineage NA sequences revealed five vi-
ruses with the following AASs: G104E/G, E105K/E, G243D/G or
G407S (Table S3). The latter AAS, was also found in three B/
Yamagata-lineage NA sequences (Table S3). Moreover, two B/
Yamagata-lineage NA sequences contained D197N or H134Y AAS.
Notably, NA H134Y AAS in a B/Victoria-lineage virus (Table 2)
conferred HRI by peramivir indicating a lineage-specific effect
(Farrukee et al., 2015). One B/Victoria- and one B/Yamagata-lineage
virus contained NAH273Q or H273NAAS, respectively. The fact that
both viruses exhibited NI suggests that these AASs are not likely to
affect drug susceptibility.
Overall, NA sequence analysis of the viruses tested in NAI assay
showed good agreement between these two methods. Notably,
sequencing allowed the detection of oseltamivir-resistant NA
H275Y AAS subpopulations in virus isolates exhibiting NI and
revealed selection of NA variants due to tissue-culture selection.
Lastly, analysis was carried out on 4698 (34.8%) NA sequences
that belonged to viruses not tested by NAI assay. Of 2371 A(H1N1)
pdm09 sequences, 40 (1.7%) contained H275Y, five of which were
H275Y/H mixtures with one containing a dual AAS, H275Y/
H þ S247S/N (Table S4). A single virus, collected in the Russian
Federation, carried NA S247R AAS that conferred RI/HRI by all four
NAIs (Tables 1 and S4). The detection frequency of A(H1N1)pdm09
viruses carrying NA AASs associated with RI/HRI was similar among
NAI assay-tested and sequence analysis-tested viruses (1.8% vs 1.7%,
respectively).
Of 815 A(H3N2) NA sequences analysed, one (0.1%), collected in
the United Kingdom, had E119V AAS (Table S4).
Among 1147 B/Victoria-lineage NA sequences, nine (0.7%) had
the following AASs: E105K, D197N, I221V, K360E, D432G or N294S
L.V. Gubareva et al. / Antiviral Research 146 (2017) 12e20 19(Table S4). No substitutions were detected in NA sequences of 93
intra-lineage reassortants (B/Victoria-lineage NA). Of 365 B/Yama-
gata-lineage sequences, two (0.5%) contained D197N or N294S
AASs (Table S4).
8. Concluding remarks
This is the fourth global update on seasonal influenza suscep-
tibility to NAIs conducted by the WHO-AVWG of GISRS. The NAI
assay data were generated by five WHO CCs on samples received
from GISRS laboratories. In addition, NA sequences deposited in
public databases by WHO CCs, NICs and other laboratories were
interrogated to identify molecular changes known or suspected to
alter susceptibility to NAIs.
Overall, the detection of seasonal influenza viruses exhibiting
decreased susceptibility to NAIs remained low (~0.09%). Consistent
with the previous global updates, the frequency of viruses dis-
playing RI or HRI was higher (~1.8%) among A(H1N1)pdm09 vi-
ruses, with the majority of such viruses containing NA H275Y AAS.
Available information indicates that many of these viruses were
collected from patients not exposed to NAIs (Tables 1 and S1). This
finding is in agreement with previous reports on the limited
transmission of oseltamivir-resistant viruses containing NA H275Y
AAS (Takashita et al., 2015b). Three other A(H1N1)pdm09 viruses,
collected inwidely-dispersed regions of the world, contained a rare
NA S247R AAS that conferred RI/HRI against all four NAIs; the AAS
was detected in the corresponding clinical specimens. Based on
recent in silico studies (Mandal et al., 2017), this AAS was predicted
to adversely affect binding of zanamivir and oseltamivir.
Another new NA H134N AAS was found in three B/Victoria-
lineage viruses from Lao DPR that displayed HRI by zanamivir,
peramivir and laninamivir (Baranovich et al., 2017). Presence of NA
H134N AAS was confirmed in the respective clinical specimens, as
for NA S247R AAS in A(H1N1)pdm09 viruses, thus ruling out their
emergence due to tissue-culture selection.
Sequence analysis of those viruses displaying NI revealed that
the NA changes detected fell into the following categories: 1) NA
variants previously associated with RI/HRI that were present in a
mix with wildtype (e.g. H275Y/H), but with too low amount of
mutant to be detected by NAI assay; 2) NA variants previously
shown to display borderline NI/RI (e.g. D197N); or 3) NA variants
carrying changes associated with tissue-culture selection (e.g.
E119K).
Likely due to a greater use of next-generation sequencing
technologies by NICs globally, as well as, new initiatives (e.g. the
Influenza Monitoring Vaccine Effectiveness (I-MOVE) program in
Europe, Advanced Molecular Detection (AMD) in the USA) greater
numbers of NA sequences are being deposited in databases. The
number of sequences available for analysis during 2015e16
doubled compared to 2014e15; with a significant increase in the
number of sequences from original clinical specimens. By
comparing sequences generated from a virus isolate and the cor-
responding clinical specimen, we can determine if changes occur
during virus isolation. This information improves the quality of
drug susceptibility data by allowing removal of artefacts associated
with tissue-culture selection.
While the list of NA changes reported to confer RI/HRI is
growing (Hurt et al., 2016; Meijer et al., 2014; Takashita et al.,
2015b), and the current list posted on the GISRS website needs
updating, interpretation of sequencing data remains a challenge in
the light of inadequate information on whether a particular NA
change produces a consistent effect. Additional studies employing
recombinant NA or reverse genetically engineered viruses may be
needed to delineate the impact of the listed changes on phenotype
assessed by NAI assay. Another limitation is the lack of informationregarding the composition of virus populations; in virus prepara-
tions containing mixes, NI phenotype can be a reflection of the
higher enzymatic activity of the wildtype subpopulation, which
may obscure the presence of the dominant NA variant subpopula-
tion (Mishin et al., 2014).
Based on available laboratory data, ~99% of seasonal influenza
viruses displayed NI by all NAIs, indicating that these drugs
continue to be an appropriate choice for the treatment of influenza
virus infection.
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